Rating Change
Stifel analysts reiterated a Hold rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on July 21, 2026.
reiterateNASDAQ:ACAD
Stifel Reiterates Hold Rating on ACADIA Pharmaceuticals Inc. (ACAD)
Rating Change Stifel analysts reiterated a Hold rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on July 21, 2026. Market Context ACADIA Pharmaceuticals Inc.
Market Context
ACADIA Pharmaceuticals Inc. operates in the Healthcare sector. The stock currently trades at $25.43 with a market capitalization of $4.2B.
Analyst coverage from Stifel provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ACADIA Pharmaceuticals Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for ACADIA Pharmaceuticals Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 21, 2026 | BMO Capital | Outperform | N/A |
| Jul 21, 2026 | Stifel | Hold | N/A |
| Jul 07, 2026 | RBC Capital | Outperform | N/A |
| Jun 30, 2026 | B of A Securities | Buy | N/A |
| Jun 29, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ACAD Stock Page
Frequently Asked Questions
What does a Hold rating mean for ACAD?
A Hold rating from Stifel reflects the analyst's outlook on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ACAD forecast page.